No Data
No Data
Leerink Partners Maintains Nanobiotix(NBTX.US) With Buy Rating, Announces Target Price $9
NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
Nanbotix Shares Are Trading Higher After the Company Announced Funding Obligations Ammendents to a Global Licensing Agreement Which Will Strengthen Its Finances.
Express News | Nanbotix Shares Are Trading Higher After the Company Announced Funding Obligations Ammendents to a Global Licensing Agreement Which Will Strengthen Its Finances
Express News | Nanobiotix SA : Leerink Partners Cuts Target Price to $9 From $11
Strategic Licensing Amendment With Janssen Bolsters Nanobiotix's Financial Outlook and Justifies Buy Rating